Cardiac Rupture: A Deadly Complication of Myocardial Infarction Caused by Cells Bordering Damaged Heart Tissue
Cardiac rupture, a devastating complication of myocardial infarction, is caused by a sequence of mechanical and cellular events involving cells bordering the damaged heart tissue.
New Study Finds Erythritol, a Common Sugar Substitute, May Increase Risk of Blood Clots and Heart Disease
Consuming erythritol, a widely used sugar substitute, may increase the risk of blood clots and cardiovascular events by enhancing platelet activation and aggregation.
Cardiac Amyloidosis: A Potentially Underdiagnosed Cause of Heart Failure
Cardiac amyloidosis, though considered rare, may be more prevalent than commonly thought and should be considered in the differential diagnosis for patients presenting with heart failure, especially those with unusual responses to standard treatments.
Navigating the Evolving Landscape of Durable Mechanical Circulatory Support: Insights on Patient Selection, Outcomes, and Future Advancements
The field of durable mechanical circulatory support (MCS) is navigating a complex landscape, balancing the benefits and challenges of device advancements, patient selection, and the impact of policy changes on access to heart transplantation.
Colchicine's Potential in Reducing Cardiovascular Risks: Emerging Evidence and Clinical Implications
Colchicine, an anti-inflammatory drug, has shown promise in reducing the risk of major adverse cardiovascular events (MACE) in patients with established atherosclerotic disease or multiple cardiovascular risk factors.
Updated Expert Consensus on Catheter and Surgical Ablation Strategies for Atrial Fibrillation
The updated expert consensus statement provides practical advice to optimize the selection and management of patients undergoing catheter or surgical ablation for atrial fibrillation, incorporating recent advancements in techniques and technologies.
Novel PCSK9 Inhibitor Lerodalcibep Demonstrated Significant LDL Cholesterol Reduction of Over 50% in High-Risk Cardiovascular Patients
Lerodalcibep, a novel PCSK9 inhibitor, reduced LDL cholesterol by over 50% in patients with or at high risk for cardiovascular disease, providing a more convenient and effective treatment option compared to existing therapies.
Initiating Inclisiran Early Leads to Significantly Better Long-Term LDL Reduction Compared to Usual Care in Patients with Atherosclerotic Cardiovascular Disease
Initiating the cholesterol-lowering drug inclisiran earlier in the treatment pathway leads to significantly better long-term low-density lipoprotein (LDL) reduction compared to usual care in patients with atherosclerotic cardiovascular disease (ASCVD).
Alcohol-Mediated Renal Denervation Shows Modest but Significant Blood Pressure Reduction in Patients with Uncontrolled Hypertension
Alcohol-mediated renal denervation significantly reduces 24-hour ambulatory systolic blood pressure in patients with uncontrolled hypertension, but the overall results are not as promising as researchers had hoped.
Aldose Reductase Inhibitor AT-001 Shows Potential to Stabilize Early-Stage Asymptomatic Diabetic Cardiomyopathy in Randomized Trial
The ARISE-HF trial found that the aldose reductase inhibitor AT-001 did not significantly outperform placebo in preventing deterioration of peak oxygen uptake (peak VO2) in patients with early-stage asymptomatic diabetic cardiomyopathy, but showed promising signals of benefit, particularly in a prespecified subgroup not taking certain antidiabetic medications.
© 2024 by Linnk AI